13G Filing: Sabby Capital and Arca Biopharma Inc. (ABIO)
Sabby Healthcare Master Fund, Ltd | 0 | 446,052 | 0 | 446,052 | 446,052 | 3.80 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 00211Y407 1.
Arca Biopharma Inc. (ABIO)
Get Email AlertsHedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 53,737 | $124 | +35% | 0% |
| 2. | 36,800 | $85 | +28% | 0% | |
| 3. | 12,400 | $29 | -41% | 0% | |
| 4. | Millennium Management Israel Englander | 11,424 | $26 | -60% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.30 | 42,914 | Other | 2,482,117 | 2022-05-16 | Filing | |
| $2.29 | 14,000 | Other | 2,439,203 | 2022-05-13 | Filing | |
| $2.27 | 27,922 | Other | 2,425,203 | 2022-05-12 | Filing | |
| $2.29 | 24,596 | Other | 2,397,281 | 2022-05-11 | Filing | |
| $2.28 | 20,979 | Other | 2,372,685 | 2022-05-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.50 | 482 | Officer | 13,153 | 2018-04-03 | Filing | |
| $0.50 | 1,114 | Officer | 0 | 2018-04-02 | Filing | |
| $0.72 | 410 | Officer | 13,635 | 2018-02-28 | Filing | |
| $0.53 | 161 | Officer | 1,114 | 2018-02-27 | Filing | |
| $0.53 | 41,331 | Large Shareholder | 0 | 2018-02-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 459,562 | $1,057 | 0% | |
| 2. | 269,877 | $620 | 0% | |
| 3. | 96,326 | $221 | 0% | |
| 4. | 69,937 | $161 | 0% | |
| 5. | 58,500 | $135 | 0% |
News See All
Venrock’s Latest Pick Shows There Are More Biotech Opportunities to Explore
Biotech is a hot segment right now and even though it has many opportunities, it is also associated with a lot of risks.
RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech
The biotechnology industry is up by more than 50% over the last year, but these towering returns don't come without great risk and volatility.
Billionaire Hedge Funds
